PMN

ProMIS Neurosciences Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website romisneurosciences.com
Employees(FY) 6
ISIN CA74346M4065

Performance

+1.76%

+0.72%

-22.7%

-45.95%

-13.29%

YTD

-30.75%

Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Advanced Technical Analysis

Technical Analysis of PMN 2024-11-20

The Moving Average Score of 6 indicates a strong bearish sentiment, while the Oscillators Score of 53 suggests a neutral stance. However, the overall Technical Score of 30 reinforces a bearish outlook, indicating that the stock may face downward pressure in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PMN

Stock Rank

Recent News & Updates

2024-11-13 20:15
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights(Globenewswire)
2024-11-11 18:00
ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference(Globenewswire)
2024-10-29 20:00
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference(Globenewswire)
2024-10-13 02:58
ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now(Insidermonkey)
2024-09-11 19:00
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences(Globenewswire)
2024-09-04 19:00
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-11 19:30
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-08-07 19:00
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights(Globenewswire)
2024-08-05 19:00
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology(Globenewswire)
2024-07-31 19:00
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024(Globenewswire)
2024-07-29 20:30
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference(Globenewswire)
2024-07-25 20:35
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial(Globenewswire)
2024-07-25 20:30
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing(Globenewswire)
2024-05-14 21:54
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024(Investorplace)
2024-05-14 04:01
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights(Globenewswire)
2024-04-29 19:00
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies(Globenewswire)
2024-04-08 19:00
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS(Globenewswire)
2024-04-03 19:00
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April(Globenewswire)
2024-04-01 10:53
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023(Investorplace)
2024-04-01 04:15
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights(Globenewswire)
2024-03-10 19:00
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio(Globenewswire)
2024-02-21 18:00
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference(Globenewswire)
2024-01-21 18:00
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine(Globenewswire)
2024-01-07 18:00
ProMIS Neurosciences Issues Letter to Shareholders(Globenewswire)
2024-01-02 18:00
ProMIS Neurosciences, Inc. Announces Leadership Transition(Globenewswire)
2023-12-19 18:00
ProMIS Neurosciences Announces Publication on Novel Target for ALS(Globenewswire)
2023-11-19 18:00
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease(Globenewswire)
2023-11-14 03:30
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights(Globenewswire)
2023-09-07 19:00
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing(Yahoo Finance)
2023-09-06 00:18
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.